26.15

1.68% 0.4119

Denali Therapeutics Inc (DNLI)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché DNLI Giù? Forum Previsione

Precedente Chiudi:

$25.74

Aprire:

$25.93

Volume 24 ore:

962.32K

Relative Volume:

0.55

Capitalizzazione di mercato:

$4.14B

Reddito:

$1.27M

Utile/perdita netta:

$-508.02M

Rapporto P/E:

-9.0783

EPS:

-2.8807

Flusso di cassa netto:

$-419.23M

1 W Prestazione:

+1.76%

1M Prestazione:

+34.08%

6M Prestazione:

+54.41%

1 anno Prestazione:

+83.67%

Intervallo 1D:

$25.36

$26.76

Intervallo di 1 settimana:

$25.05

$26.80

Portata 52W:

$12.58

$26.80

Denali Therapeutics Inc Stock (DNLI) Company Profile

Nome

Denali Therapeutics Inc

Settore

Healthcare (1100)

Industria

Biotechnology (615)

Telefono

(650) 866-8547

Indirizzo

161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO

Dipendente

507

Cinguettio

Prossima data di guadagno

2026-08-10

Ultimi documenti SEC

DNLI's Discussions on Twitter

Compare DNLI vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
DNLI Denali Therapeutics Inc	26.11	4.09B	1.27M	-508.02M	-419.23M	-2.8807
VRTX Vertex Pharmaceuticals Inc	522.41	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.94	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	915.98	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	320.29	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	189.97	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-26	Reiterato	H.C. Wainwright	Buy
2026-02-24	Iniziato	Wolfe Research	Peer Perform
2026-01-07	Ripresa	UBS	Buy
2025-04-10	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2025-03-07	Ripresa	Morgan Stanley	Overweight
2025-02-11	Iniziato	Deutsche Bank	Buy
2025-01-07	Iniziato	Robert W. Baird	Outperform
2025-01-03	Iniziato	William Blair	Outperform
2024-12-16	Aggiornamento	Stifel	Hold → Buy
2024-10-10	Ripresa	Raymond James	Mkt Perform
2024-10-07	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2023-12-13	Iniziato	Citigroup	Buy
2023-11-20	Ripresa	JP Morgan	Overweight
2023-10-24	Ripresa	Cantor Fitzgerald	Overweight
2023-09-06	Iniziato	B. Riley Securities	Buy
2023-01-30	Iniziato	SVB Securities	Outperform
2022-12-05	Iniziato	Cowen	Outperform
2022-11-02	Aggiornamento	BTIG Research	Neutral → Buy
2022-11-02	Iniziato	BofA Securities	Buy
2022-06-23	Iniziato	Berenberg	Buy
2021-12-10	Ripresa	Raymond James	Mkt Perform
2021-09-21	Iniziato	Oppenheimer	Outperform
2021-09-01	Iniziato	SMBC Nikko	Outperform
2021-05-18	Iniziato	UBS	Buy
2021-02-26	Reiterato	H.C. Wainwright	Buy
2021-02-10	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2020-11-11	Reiterato	H.C. Wainwright	Buy
2020-10-16	Downgrade	BTIG Research	Buy → Neutral
2020-09-14	Ripresa	JP Morgan	Overweight
2020-08-20	Reiterato	H.C. Wainwright	Buy
2020-03-13	Aggiornamento	Evercore ISI	In-line → Outperform
2020-02-28	Aggiornamento	Wedbush	Neutral → Outperform
2020-02-24	Iniziato	Jefferies	Buy
2020-02-19	Iniziato	Stifel	Hold
2020-01-27	Aggiornamento	Goldman	Neutral → Buy
2019-09-26	Iniziato	Wedbush	Neutral
2019-09-13	Iniziato	Nomura	Buy
2019-08-09	Iniziato	BTIG Research	Buy
2019-06-26	Iniziato	H.C. Wainwright	Buy
2018-11-15	Iniziato	Cantor Fitzgerald	Overweight
2018-11-12	Iniziato	Janney	Buy
2018-03-12	Downgrade	Evercore ISI	Outperform → In-line
2018-01-02	Iniziato	Evercore ISI	Outperform
2018-01-02	Iniziato	Goldman	Neutral
2018-01-02	Iniziato	JP Morgan	Overweight
2018-01-02	Iniziato	Morgan Stanley	Overweight

Mostra tutto

Denali Therapeutics Inc Borsa (DNLI) Ultime notizie

Jul 06, 2026

Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com

Jul 06, 2026

Trading Systems Reacting to (DNLI) Volatility - Stock Traders Daily

Jul 06, 2026

DNLIDenali Therapeutics Inc Volatility & Greeks - Finviz

Jul 06, 2026

Jul 05, 2026

Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally - Sahm

Jul 05, 2026

Jul 03, 2026

Denali Therapeutics stock stays focused on pipeline progress. - AD HOC NEWS

Jul 03, 2026

Jul 01, 2026

Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK - Barchart.com

Jul 01, 2026

Jun 29, 2026

Denali to sell priority review voucher for $195M cash boost - MSN

Jun 29, 2026

Jun 27, 2026

Enterprise value to EBIT forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView

Jun 27, 2026

Price to sales forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView

Jun 27, 2026